Trinity Delta Comments on HUTCHMED FY2027 Earnings

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) – Trinity Delta issued their FY2027 earnings per share (EPS) estimates for shares of HUTCHMED in a note issued to investors on Tuesday, June 9th. Trinity Delta analyst L. Gregorek expects that the company will post earnings per share of $0.31 for the year. The consensus estimate for HUTCHMED’s current full-year earnings is $0.47 per share.

HCM has been the topic of a number of other research reports. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Morgan Stanley set a $13.60 price objective on HUTCHMED in a report on Thursday, May 28th. Bank of America decreased their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Finally, Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, HUTCHMED currently has an average rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Stock Performance

Shares of HCM stock opened at $10.87 on Thursday. The stock’s fifty day moving average is $13.28 and its two-hundred day moving average is $13.98. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. HUTCHMED has a fifty-two week low of $10.40 and a fifty-two week high of $19.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HCM. Blue Trust Inc. increased its stake in shares of HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after acquiring an additional 4,378 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE increased its stake in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of HUTCHMED by 34.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after acquiring an additional 5,538 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of HUTCHMED in the 1st quarter worth $365,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.